RIL
CPRX

Rothschild Investment LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

Rothschild Investment LLC’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63K Buy
2,006
+3
+0.1% +$89 ﹤0.01% 1192
2026
Q1 		$49.6K Buy
2,003
+59
+3% +$1.41K ﹤0.01% 1121
2025
Q4 		$45.4K Buy
1,944
+284
+17% +$6.33K ﹤0.01% 1057
2025
Q3 		$32.7K Buy
1,660
+1,520
+1,086% +$31.3K ﹤0.01% 1114
2025
Q2 		$3.04K Sell
140
-40
-22% -$944 ﹤0.01% 1778
2025
Q1 		$4.37K Buy
180
+60
+50% +$1.35K ﹤0.01% 1506
2024
Q4 		$2.5K Buy
120
+30
+33% +$644 ﹤0.01% 1665
2024
Q3 		$1.79K Buy
90
+50
+125% +$927 ﹤0.01% 1789
2024
Q2 		$620 Buy
40
+30
+300% +$467 ﹤0.01% 1885
2024
Q1 		$159 Buy
+10
New +$151 ﹤0.01% 1866

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rothschild Investment LLC's CPRX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Catalyst Pharmaceutical (CPRX) stake by 0.15% in Q2 2026, buying an estimated $89 and bringing the position to 2,006 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Rothschild Investment LLC first reported a position in CPRX in Q1 2024 and has held it in 10 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Rothschild Investment LLC held 2,006 shares of Catalyst Pharmaceutical worth $63K as of Q2 2026.
  • Rothschild Investment LLC bought 3 Catalyst Pharmaceutical shares in Q2 2026, an estimated $89.
  • Catalyst Pharmaceutical made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1192 holding.
  • Rothschild Investment LLC first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.